U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07644039) titled 'Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies' on June 08.
Brief Summary: The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembrolizumab in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investigator's assessment in participants in other cohorts.
Study Start Date: May 21
Study Type: INTERVENTIONAL
Condition:
Advanced Malignancies
Intervention:
DRUG: Pembrolizumab
Intravenous infusion.
DRUG: PM54
In...